LG CNS announced on Wednesday that it is expanding its artificial intelligence (AI)-based AI Transformation (AX) business into the pharmaceutical and biotech sectors, beyond its traditional strongholds in finance, manufacturing, public sector, and defense.
The company has been selected as a service provider for the Ministry of Health and Welfare’s K-AI New Drug Development Preclinical and Clinical Model Development Project (R&D). This government-funded initiative, with an investment of approximately 37.1 billion KRW (about 25.2 million USD) over four years and three months, tasks LG CNS with developing a platform for designing and supporting clinical trials in new drug development.
The platform will leverage LG CNS’s Agentic AI technology to integrate and manage various AI models for new drug development from different institutions.
To ensure data security, the platform employs a Federated Learning approach. This method allows for collaborative learning without exporting data externally, potentially accelerating drug development and improving success rates by connecting preclinical and clinical data flows.
An LG CNS spokesperson highlighted the significance of this project, noting that new drug development typically takes 10-15 years with a clinical failure rate of about 90%. The company aims to enhance drug development productivity by combining bio AI technologies, such as protein structure analysis and design, with their proprietary platform.
In the private sector, LG CNS has driven innovation in pharmaceutical operations through a quality evaluation automation project with Chong Kun Dang.
Using its enterprise AI development platform AgenticWorks, LG CNS created an Annual Product Quality Review (APQR) Automation Service, significantly streamlining the report creation process.
The APQR automation service utilizes about 30 AI agents that autonomously collaborate on data collection, analysis, validation, and report writing. It directly extracts information from core databases such as Quality Management Systems (QMS) and Laboratory Information Management Systems (LIMS) to generate reports automatically.
Kim Tae-hoon, Vice President of LG CNS’s AI Cloud Business Division, stated that its pharmaceutical and biotech AX technology is gaining recognition from both the government and pharmaceutical companies. It aims to become a game-changer that enhances the competitiveness of the domestic biotech industry and revolutionizes customer value through the Agentic AI technology.